Control of tumor-associated macrophage responses by nutrient acquisition and metabolism

X Zhang, L Ji, MO Li - Immunity, 2023 - cell.com
Metazoan tissue specification is associated with integration of macrophage lineage cells in
sub-tissular niches to promote tissue development and homeostasis. Oncogenic …

TGFβ control of immune responses in cancer: a holistic immuno-oncology perspective

BG Nixon, S Gao, X Wang, MO Li - Nature Reviews Immunology, 2023 - nature.com
The immune system responds to cancer in two main ways. First, there are prewired
responses involving myeloid cells, innate lymphocytes and innate-like adaptive lymphocytes …

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy

R Yang, L Sun, CF Li, YH Wang, J Yao, H Li… - Nature …, 2021 - nature.com
The two T cell inhibitory receptors PD-1 and TIM-3 are co-expressed during exhausted T cell
differentiation, and recent evidence suggests that their crosstalk regulates T cell exhaustion …

Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy

FG Herrera, C Ronet, M Ochoa de Olza, D Barras… - Cancer discovery, 2022 - AACR
Developing strategies to inflame tumors is critical for increasing response to immunotherapy.
Here, we report that low-dose radiotherapy (LDRT) of murine tumors promotes T-cell …

Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases

KM Sullivan, X Jiang, P Guha, C Lausted, JA Carter… - Gut, 2023 - gut.bmj.com
Objective Programmed cell death protein 1 (PD-1) checkpoint inhibition and adoptive
cellular therapy have had limited success in patients with microsatellite stable colorectal …

Multi-omics characterization of the 4T1 murine mammary gland tumor model

B Schrörs, S Boegel, C Albrecht, T Bukur… - Frontiers in …, 2020 - frontiersin.org
Background: Tumor models are critical for our understanding of cancer and the development
of cancer therapeutics. The 4T1 murine mammary cancer cell line is one of the most widely …

An in situ hydrogel-mediated chemo-immunometabolic cancer therapy

B Wang, J Chen, JS Caserto, X Wang, M Ma - Nature Communications, 2022 - nature.com
Metabolic reprogramming of the tumor microenvironment (TME) and poor immunogenicity
are two of the challenges that cancer immunotherapies have to overcome for improved …

Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors

B Belmontes, DV Sawant, W Zhong, H Tan… - Science translational …, 2021 - science.org
Therapeutic approaches are needed to promote T cell–mediated destruction of poorly
immunogenic,“cold” tumors typically associated with minimal response to immune …

Harnessing the predictive power of preclinical models for oncology drug development

A Honkala, SV Malhotra, S Kummar… - Nature reviews Drug …, 2022 - nature.com
Recent progress in understanding the molecular basis of cellular processes, identification of
promising therapeutic targets and evolution of the regulatory landscape makes this an …

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth

D Doleschel, S Hoff, S Koletnik, A Rix, D Zopf… - Journal of Experimental …, 2021 - Springer
Background Patients with advanced colorectal cancer (CRC) have a poor prognosis.
Combinations of immunotherapies and anti-angiogenic agents are currently being …